A decision flow tree for the patient with relapsed or progressive FL is presented in Figure 2 ... grade 3 or 4 adverse events, specifically neutropenia and thrombocytopenia. Follicular lymphoma ...

The new use is the third for Kymriah (tisagenlecleucel) in the EU and offers patients with grade 1, 2 and 3A follicular lymphoma that has returned after two or more prior treatments a new ...

SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to ...

The inMIND trial was conducted in 26 countries and included 548 patients with follicular lymphoma ... arm and 45.2% in the placebo arm. The most common grade 3 or 4 treatment-emergent adverse ...